Physician profile
Gary W Sides
NPI 1952309791
$2,316.87
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $272 · 2021: $759 · 2022: $809.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,278.82 | 2021-2022 | |
| Novo Nordisk INC | $198.28 | 2019-2021 | |
| Amarin Pharma, INC. | $156.70 | 2019-2021 | |
| Glaxosmithkline, LLC. | $152.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.90 | 2019-2021 | |
| Astellas Pharma US INC | $56.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.61 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.76 | 2019-2020 | |
| Lilly USA, LLC | $37.31 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $36.10 | 2019-2020 | |
| Amgen INC. | $35.37 | 2019 | |
| Pfizer INC. | $31.68 | 2019-2020 | |
| Mylan Specialty L.P. | $24.29 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $13.13 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.43 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.10 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.34 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Sides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.